A Phase III Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-1439A Once-Daily Versus ATRIPLA Once-Daily in Treatment-Naive HIV-1 Infected Subjects
Latest Information Update: 21 Feb 2024
At a glance
- Drugs Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms DRIVE-AHEAD
- Sponsors Merck Sharp & Dohme Corp.
- 22 Sep 2023 Status changed from active, no longer recruiting to completed.
- 26 Oct 2022 Results (of three phase 3 studies DRIVE-FORWARD, DRIVE- AHEAD and DRIVE-SHIFT) assessing Factors associated with weight loss or stable weight after continuing or switching to a doravirine-based regimen presented at the 16th International Congress on Drug Therapy and HIV Infection
- 26 Oct 2022 Results (of open-label extensions of the two studies DRIVE-AHEAD and DRIVE-FORWARD ) Resolution of neuropsychiatric adverse events after switching to a doravirine-based regimen presented at the 16th International Congress on Drug Therapy and HIV Infection